Skip to main content
Download PDF
Download ePub

DNMT1 SNPs (rs2114724 and rs2228611) associated with positive symptoms in Chinese patients with schizophrenia

Annals of General Psychiatry volume 22, Article number: 40 (2023) Cite this article

Abstract

Objective

Schizophrenia is a serious mental disorder with complex clinical manifestations, while its pathophysiological mechanism is not fully understood. Accumulated evidence suggested the alteration in epigenetic pathway was associated with clinical features and brain dysfunctions in schizophrenia. DNA methyltransferases (DNMTs), a key enzyme for DNA methylation, are related to the development of schizophrenia, whereas the current research evidence is not sufficient. The aim of study was to explore the effects of gene polymorphisms of DNMTs on the susceptibility and symptoms of schizophrenia.

Methods

The study was case–control study that designed and employed the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) as the diagnostic standard. 134 hospitalized patients with schizophrenia in the Third People's Hospital of Zhongshan City from January 2018 to April 2020 (Case group) as well as 64 healthy controls (Control group) from the same region were involved. Single nucleotide polymorphisms (SNPs) of DNMT1 genes (r s2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) were determined with massARRAY. Linkage disequilibrium analysis and haplotype analysis were performed, and genotype and allele frequencies were compared. The Hardy–Weinberg equilibrium was tested by the Chi-square test in SPSS software (version 20.0, SPSS Inc., USA). The severity of clinical symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS). The correlation between DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs2424932, rs1569686, rs6119954 and rs2424908) and clinical features was analyzed.

Results

There were no significant differences in genotype, allele frequency and haplotype of DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) between the case and healthy control group. There were significant differences in the PANSS total positive symptom scores, P3 (hallucinatory behavior), P6 (suspicious/persecution), G7 (motor retardation), and G15 (preoccupation) in patients with different DNMT1 gene rs 2114724 and rs 2228611 genotypes. The linkage disequilibrium analysis of gene polymorphic loci revealed that rs 2114724–rs 2228611 was complete linkage disequilibrium, and rs 1569686–rs 2424908, rs 2424932–rs 1569696 and rs 2424932–rs 2424908 were strongly linkage disequilibrium.

Conclusion

The polymorphisms alteration in genetic pathway may be associated with development of specific clinical features in schizophrenia.

Introduction

Schizophrenia is a chronic and debilitating mental disorder affecting more than 20 million individuals worldwide, with significant socioeconomic consequences [1, 2]. One of the main features of schizophrenia is the dissociation of thoughts, concepts, identities, and emotions [3,4,5,6], associated with dysregulated neural pathways in the brain that lead to positive and negative symptoms [4, 6, 7]. The etiology of schizophrenia is multifactorial, involving genetic predisposition, environmental factors, and epigenetic modifications [6]. It is estimated that schizophrenia has a heritability range of 79–81% [8]. Genetic risk loci have been identified in non-coding areas such as promoters and introns, indicating that gene regulation is crucial for the onset of psychotic disorders [9]. In the case of schizophrenia, research has identified a number of genetic risk factors that are associated with altered gene expression patterns [10,11,12], which may be influenced by epigenetic modifications [9]. Twin studies have also provided evidence that epigenetic factors may be involved in the development of schizophrenia [13].

Epigenetic modifications, mainly DNA methylation or histone modifications, are involved in gene regulation. Among these, DNA methylation is the most extensively investigated [14]. DNA methylation occurs through the covalent binding of methyl groups to cytosine-guanine dinucleotides (CpG) [15]. Several genes, including GAD1 [16], COMT [17], RELN [18], BDNF [19], CHRNA7 [20], SOX10 [21], EGR1 [22], have been identified as potential candidates for DNA methylation in schizophrenic patients. DNA methylation is established and maintained by methyltransferases, such as DNMT1, DNMT3A, and DNMT3B [23]. DNMTs were first recognized as stable repressive marks, which are important mechanisms for gene silencing during progression and the cycle of life [24]. It has been suggested that patients with schizophrenia may have DNMT gene dysfunction.

Studies have shown that DNMTs are essential for the generation of mature, functioning germ cells, and appropriate embryonic development [25, 26]. Abnormal DNA methylation patterns have been linked to an increased risk of certain human diseases in individuals with a hereditary predisposition [27]. Genetic variations, such as single nucleotide polymorphisms (SNPs), have been strongly associated with schizophrenia in several family studies [28, 29]. Recent case–control studies indicated a significant association between minor alleles of DNMT1 (rs2114724 and rs2228611), DNMT3B (rs2424932 and rs1569686) and susceptibility of schizophrenia, while it is rare [30].

Previous studies have focused on the three active DNMT enzymes: DNMT1, DNMT3A, and DNMT3B. Some investigations have linked schizophrenia to polymorphisms within these enzymes, but there is still considerable ambiguity regarding the relationship between these polymorphisms and the clinical features of schizophrenia. DNMT SNPs prevalence in southern Chinese populations has not been reported yet. Therefore, the aim of the present study was to explore the effects of DNMT gene polymorphisms on schizophrenia susceptibility and symptoms in this population.

Materials and methods

Patient and control samples

Patients or their legal guardians provided informed consent after receiving authorization from the ethics committee of Zhongshan Third People’s Hospital for this study. The investigation focused on patients with schizophrenia who were treated at the hospital between 2018 and 2020. Participants were included if they met the following criteria: a diagnosis of schizophrenia as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, made by two attending physicians with consistent training, age between 16 and 60 years, and Han ethnicity. The study excluded patients with diabetes, hypertension, cancer, and other nervous system or mental diseases. However, other mental disorders were not excluded.

The control group at Zhongshan City’s Third People’s Hospital consisted of physical exam mentally healthy patients, employees, nurses, and volunteers. To be included in the control group, subjects had to meet the following criteria: no history of mental illness, no family history of mental illness, pass a physical exam, Han ethnicity, and between 18 and 60 years of age after psychological screening. The control group excluded adopted or single-parent children with unknown family histories, as well as individuals with serious somatic disorders such as diabetes, hypertension, or cancer.

Methods

The experimental methods used in this research included the collection of general data and clinical information, evaluation of psychotic symptoms, genomic DNA extraction, primer creation, PCR amplification, alkaline phosphatase treatment, single-base extension reaction, resin purification, chip sampling, mass spectrometric detection, and data analysis, which were based on past studies [31, 32].

The collected data were sorted and evaluated using the statistical program SPSS 20.0 (IBM, Armonk, NY, USA). The analysis of variance was performed, and results were presented as mean and standard deviation since the data exhibited normal distribution. Nonparametric statistical approaches were applied to non-normal data, and the results were expressed numerically as the median value (upper quartile, lower quartile). The genotype frequency was analyzed using the Chi-square test. regarding as categorical data. Hardy–Weinberg equilibrium was examined using SPSS 20.0 Chi-square test, and genotype and allele frequencies were compared between the schizophrenia and control groups. The linkage disequilibrium (LD) and pairwise LD coefficients in DNMT1 and DNMT3B were implemented with Haploview 4.2. ORs and confidence intervals (CIs) were computed for 95% of the data, and G*Power 3.1 was used for power analysis.

Results

Test of Hardy–Weinberg equilibrium for DNMT1 and DNMT3B

We performed a Hardy–Weinberg equilibrium analysis on the genotype data of 134 individuals with schizophrenia, focusing on six DNMT gene polymorphisms (rs2114724, rs2228611, rs2424932, rs1569686, rs6119954, and rs2424908). The results, presented in Tables 1 and 2, indicate that the genotype frequencies at these loci did not deviate significantly from the predicted population frequencies (p > 0.05). No outliers were identified as the cause of these results.

Table 1 Hardy–Weinberg equilibrium test for DNMT1 genotypes
Full size table
Table 2 Hardy–Weinberg equilibrium test for DNMT3B genotypes
Full size table

Results of genotype and allelic analysis for DNMT1 and DNMT3B

Tables 3 and 4 demonstrate that there were no significant differences in genotype frequencies between the two groups at the DNMT1 gene loci rs2114724 and rs2228611 (p > 0.05). Likewise, no significant differences were observed in the genotype frequencies between the two groups at the DNMT3B gene loci rs2424932, rs1569686, rs6119954, and rs2424908 (p > 0.05).

Table 3 Comparison of DNMT1 rs2114724 and rs2228611 genotype frequencies between the two groups
Full size table
Table 4 Comparison of DNMT3B rs1569686, rs2424908, rs2424932 and rs6119954 genotype frequencies between the two groups
Full size table

Table 5 displays no significant differences in the frequency of the rs2114724, rs2228611, rs1569686, rs2424908, rs2424932, and rs6119954 alleles between the two groups (p > 0.05).

Table 5 Comparison of rs2114724, rs2228611, rs1569686, rs2424908, rs2424932 and rs6119954 allele frequencies between the two groups
Full size table

Linkage disequilibrium analysis for DNMT1 and DNMT3B

Genotyping for two SNPs in DNMT1 and four SNPs in DNMT3B was successful, and Fig. 1 illustrates their linkage disequilibrium (LD). The two SNPs in DNMT1 formed a block within 25 kb (chr19: 10154572-10156401), contrasting the four SNPs in DNMT3B. Due to DNMT1's strong linkage, tagged SNPs were run in Haploview.

Fig. 1
figure 1

Linkage disequilibrium (LD) pattern of DNMT1 (a) and DNMT3B (b) SNPs from Haploview analysis. The D′ values for LD are represented by the numbers inside the boxes; the miss numbers were 100. The strength of the LD between pairwise pairings of SNPs is shown by the areas that are shaded in the LD map (white represent low LD; red represent high LD)

Full size image

Haplotypes of the SNPs in DNMT1 and DNMT3B

We examined the haplotype distribution of DNMT1 (rs2114724 and rs2228611) and DNMT3B (rs1569686, rs2424908, rs2424932, and rs6119954) in both the schizophrenia and control groups. Haplotypes with a frequency of at least 3% were selected for analysis to investigate their association with schizophrenia. Two distinct DNMT1 haplotypes were identified, with the CT haplotype being the most common in both controls (68.0%) and patients (63.8%). The most common DNMT3B haplotype in both groups was GTGT (59.3% and 60.9%, respectively). The haplotype frequencies at gene loci rs2114724–rs2228611, rs2424932–rs1569686–rs6119954–rs2424908, and overall did not differ significantly between patients and controls (p > 0.05, Table 6).

Table 6 Analysis of haplotype distribution between the schizophrenia and control groups
Full size table

Analysis of the association between genotypes and clinical symptoms of schizophrenia

Table 7 displays the associations between DNMT1 (rs2114724 and rs2228611) and DNMT3B gene (rs1569686, rs2424908, rs2424932, and rs6119954) and clinical mental symptoms of schizophrenia. Statistically significant differences in PANSS overall positive symptom scores, P3 (hallucinatory behavior), P6 (suspicious/persecution), G7 (motor retardation), and G15 (preoccupation) were observed when comparing patients with different DNMT1 gene rs2114724 and rs2228611 genotypes. Moreover, significant differences were found in PANSS general symptom scores G1 (somatic concern), G5 (mannerisms and posturing), and G8 (uncooperativeness) among patients with different DNMT3B gene rs6119954 genotypes (p < 0.05). Additionally, significant differences were noted in the PANSS general symptom score G10 (disorientation) among individuals with different DNMT3B gene rs2424908 genotypes (p < 0.05).

Table 7 Relationships between different DNMT1 and DNMT3B genotypes and PANSS scores in schizophrenia group
Full size table

Evaluation of statistical power

G*Power calculated power. This sample had 92.372% power to identify a meaningful relationship (α < 0.05) with an effect size index of 0.5.

Discussion

Accumulating evidence suggests that the development of schizophrenia is influenced by the interaction of heredity and environmental factors [33]. Epigenetic mechanisms, such as DNA methylation with DNA methyltransferases (DNMTs), are crucial for the effect of environmental factors on genetic susceptible. In the dynamic procedure methylation, the DNMT1 is responsible majorly for maintaining methylation during cell division [34, 35].

This study investigated the genotype and allele distribution of DNMT1 (rs2114724 and rs2228611) and DNMT3B (rs1569686, rs2424908, rs2424932, and rs6119954) in 134 patients with schizophrenia and 64 healthy controls. The results showed no statistical difference between the case and control groups, which contradicted to the few previous study in India population [36]. The study found that the TT genotype and T allele in DNMT1 rs2114724 and the AA genotype and A allele in DNMT1 rs2228611 were associated with schizophrenia. However, there was no significant difference in genotype and allele distribution in DNMT3B gene (rs2424932, rs1569686, rs6119954, and rs2424908) between the case group and the control group. In line with study from population with shared ethical background [37], indicated that the genotype frequency and allelic frequency of DNMT1 rs2114724 and rs2228611 were also correlated with schizophrenia. Few studies employing Chinese Han population reported similar findings with the current study. For instance, Zhai et al. [38] investigated the genotype and allele distribution of DNMT1 rs2114724 and rs2228611 in a Chinese population and found no significant difference between the schizophrenic patients and healthy controls. Furthermore, Zhang Chen et al. [39] revealed that there was no statistical difference in genotype and allele distribution of DNMT3B rs2424908 between the schizophrenic case and control groups. Although the significant difference in genotype and allele distribution of DNMT3B rs6119954 was identified in the schizophrenic patients, which indicated dysfunction of DNMR3B. There are couple of reasons contribute to the discrepancies. Firstly, racial genetic background will affect on the difference in allelic frequency, according to the previous findings [38, 39]. Secondly, technology employed for identifying the genetic variation attribute partly to difference of observational results. Previous study indicated that low effective values for identifying genetic variation in promoter upstream regions with Methylated DNA Immunoprecipitation (MeDIP) comparing to microarray [40]. Finally, sample size in the literatures may contribute to variation in the findings [41].

This study used linkage disequilibrium analysis to identify an absolute linkage block between rs2114724 and rs2228611 in DNMT1 and the four loci in DNMT3B. These loci were significantly correlated with positive symptoms of schizophrenia, including hallucinatory behavior, suspicion/persecution, motor retardation, and preoccupation. This is the first report linking rs2114724 and rs2228611 in DNMT1 with positive symptoms of schizophrenia. DNMT1 gene may affect the clinical symptoms of schizophrenia by regulating the expression of genes involved in the dopaminergic and GABAergic systems [41]. Cumulating evidence has suggested that DNMT1 as well as DNMT3 established and maintained dynamically the DNA methylation in dopaminergic, GABAergic, glutamatergic, serotonergic pathways of neurotransmission, which response for regulating the clinical phenotypes [42,43,44,45,46].

Although this study provides new insights into the role of DNMTs in schizophrenia, limitations exist, and further research is necessary to validate the findings in larger samples and different populations. Future studies should also explore the specific regulatory mechanisms of DNA methylation in the development of schizophrenia.

Availability of data and materials

The original data presented in the study are available upon to enquiry from the corresponding authors.

References

  1. Stuchlik A, Sumiyoshi T. Cognitive deficits in schizophrenia and other neuropsychiatric disorders: convergence of preclinical and clinical evidence. Front Behav Neurosci. 2014;8:444.

    PubMed  PubMed Central  Google Scholar 

  2. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–858.

    Google Scholar 

  3. Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci. 2017;18:727–40.

    CAS  PubMed  Google Scholar 

  4. Kim JS, Shin KS, Jung WH, Kim SN, Kwon JS, Chung CK. Power spectral aspects of the default mode network in schizophrenia: an MEG study. BMC Neurosci. 2014;15:104.

    PubMed  PubMed Central  Google Scholar 

  5. Moskowitz A, Heim G. Eugen Bleuler’s dementia praecox or the group of schizophrenias (1911): a centenary appreciation and reconsideration. Schizophr Bull. 2011;37:471–9.

    PubMed  PubMed Central  Google Scholar 

  6. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86–97.

    PubMed  PubMed Central  Google Scholar 

  7. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383:1677–87.

    PubMed  Google Scholar 

  8. Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, Nordentoft M, Glenthøj B. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register. Biol Psychiatry. 2018;83:492–8.

    PubMed  Google Scholar 

  9. Mendizabal I, Berto S, Usui N, Toriumi K, Chatterjee P, Douglas C, Huh I, Jeong H, Layman T, Tamminga CA, et al. Cell type-specific epigenetic links to schizophrenia risk in the brain. Genome Biol. 2019;20:135.

    PubMed  PubMed Central  Google Scholar 

  10. Gusev A, Mancuso N, Won H, Kousi M, Finucane HK, Reshef Y, Song L, Safifi A, McCarroll S, Neale BM. Transcriptome wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nat Genet. 2018;50:538–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, Ruderfer DM, Oh EC, Topol A, Shah HR. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci. 2016;19:1442–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L, Kam-Thong T, Xi HS, Quan J, Chen Q. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat Neurosci. 2018;21:1117–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Cardno AG, Gottesman II. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 2000;97:12–7.

    CAS  PubMed  Google Scholar 

  14. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature. 2007;447:425–32.

    CAS  PubMed  Google Scholar 

  15. Zeng Y, Chen T. DNA methylation reprogramming during mammalian development. Genes. 2019;10:257.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Nishioka M, Bundo M, Kasai K, Iwamoto K. DNA methylation in schizophrenia: Progress and challenges of epigenetic studies. Genome Med. 2012;4:96.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Martinez-Jauand M, Sitges C, Rodriguez V, Picornell A, Ramon M, Buskila D, Montoya P. Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur J Pain. 2013;17:16–27.

    CAS  PubMed  Google Scholar 

  18. Sozuguzel MD, Sazci A, Yildiz M. Female gender specific association of the Reelin (RELN) gene rs7341475 variant with schizophrenia. Mol Biol Rep. 2019;46:3411–6.

    CAS  PubMed  Google Scholar 

  19. Janicijevic SM, Dejanovic SD, Borovcanin M. Interplay of brain-derived neurotrophic factor and cytokines in schizophrenia. Serb J Exp Clin Res. 2018;108:110–7.

    Google Scholar 

  20. Leonard S, Freedman R. Genetics of chromosome 15q13–q14 in schizophrenia. Biol Psychiatry. 2006;60:115–22.

    CAS  PubMed  Google Scholar 

  21. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, Kato T. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci. 2005;25:5376–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Hu T-M, Chen S-J, Hsu S-H, Cheng M-C. Functional analyses and effect of DNA methylation on the EGR1 gene in patients with schizophrenia. Psychiatry Res. 2019;275:276–82.

    CAS  PubMed  Google Scholar 

  23. Gowher H, Liebert K, Hermann A, Xu G, Jeltsch A. Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L. J Biol Chem. 2005;280(14):13341–8.

    CAS  PubMed  Google Scholar 

  24. Symmank J, Bayer C, Schmidt C, et al. DNMT1 modulates interneuron morphology by regulating Pak6 expression through crosstalk with histone modifications. Epigenetics. 2018;13(5):536–56.

    PubMed  PubMed Central  Google Scholar 

  25. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases DNMT3A and DNMT3B are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.

    CAS  PubMed  Google Scholar 

  26. Bourc’his D, Bestor TH. Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking DNMT3L. Nature. 2004;431:96–9.

    PubMed  Google Scholar 

  27. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610.

    CAS  PubMed  Google Scholar 

  28. Ripke S, Neale BM, Corvin A, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.

    CAS  PubMed Central  Google Scholar 

  29. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012;148(6):1223–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Saradalekshmi KR, Neetha NV, Sathyan S, Nair IV, Nair CM, Banerjee M. DNA methyl transferase (DNMT) gene polymorphisms could be a primary event in epigenetic susceptibility to schizophrenia. PLoS ONE. 2014;9(5):e98182–8.

    PubMed  PubMed Central  Google Scholar 

  31. Ping J, Zhang J, Wan J, Banerjee A, Huang C, Yu J, Jiang T, Du B. Correlation of four single nucleotide polymorphisms of the RELN gene with Schizophrenia. East Asian Arch Psychiatry. 2021;31(4):112–8. https://doiorg.publicaciones.saludcastillayleon.es/10.12809/eaap2168.

    Article  CAS  PubMed  Google Scholar 

  32. Ping J, Zhang J, Wan J, Huang C, Luo J, Du B, Jiang T. A polymorphism in the BDNF gene (rs11030101) is associated with negative symptoms in Chinese Han patients with schizophrenia. Front Genet. 2022;16(13):849227.

    Google Scholar 

  33. Palha JA, Santos NC, Marques F, et al. Do genes and environment meet to regulate cerebrospinal fluid dynamics? Relevance for schizophrenia. Front Cell Neurosci. 2012;6(8):31.

    PubMed  PubMed Central  Google Scholar 

  34. Pogribny IP, Beland FA. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci. 2009;66(14):2249–61.

    CAS  PubMed  Google Scholar 

  35. Grayson DR, Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmaeology. 2013;38(1):138–66.

    CAS  Google Scholar 

  36. Saradalekshmi KR, Neetha NV, Satyan S, et al. DNA methyltransferase (DNMT) gene polymorphisms could be a primary event in epigenetic susceptibility to schizophrenia. PLoS ONE. 2014;9(5):e98182.

    PubMed  PubMed Central  Google Scholar 

  37. Saxena S, Maroju PA, Choudhury S, Voina VC, Naik P, Gowdhaman K, Kkani P, Chennoju K, Ganesh Kumar S, Ramasubramanian C, Prasad Rao G, Jamma T, Narayan KP, Mohan KN. Functional analysis of DNMT1 SNPs (rs2228611 and rs2114724) associated with schizophrenia. Genet Res. 2021;31(2021):6698979. https://doiorg.publicaciones.saludcastillayleon.es/10.1155/2021/6698979.

    Article  Google Scholar 

  38. Zhai J, Miao Q, Gao Y, Chen M, Zhou YN, Wei XL, Li J. The relationship between DNA methyltransferase 1 gene polymorphism and cognitive function in the first episode, drug-naïve schizophrenia. Chin J Nerv Ment Dis. 2018;44:166–70.

    Google Scholar 

  39. Zhang C, Fang Y, Xie B, Cheng W, Du Y, Wang D, Yu S. DNA methyltransferase 3B gene increases risk of early onset schizophrenia. Neurosci Lett. 2009;462(3):308–11. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.neulet.2009.06.085.

    Article  CAS  PubMed  Google Scholar 

  40. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P, Assadzadeh A, Flanagan J, Schumacher A, Wang SC, Petronis A. Epigenomic profiling reveals DNA methylation changes associated with major psychosis. Am J Hum Genet. 2008;82(3):696–711.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Wu X, Ye J, Wang Z, Zhao C. Epigenetic age acceleration was delayed in schizophrenia. Schizophr Bull. 2021;47(3):803–11.

    PubMed  Google Scholar 

  42. Magwai T, Shangase KB, Oginga FO, Chiliza B, Mpofana T, Xulu KR. DNA methylation and schizophrenia: current literature and future perspective. Cells. 2021;10(11):2890. https://doiorg.publicaciones.saludcastillayleon.es/10.3390/cells10112890.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Yoshino Y, Kawabe K, Mori T, Mori Y, Yamazaki K, Numata S, Nakata S, Yoshida T, Iga J, Ohmori T, Ueno S. Low methylation rates of dopamine receptor D2 gene promoter sites in Japanese schizophrenia subjects. World J Biol Psychiatry. 2016;17(6):449–56.

    PubMed  Google Scholar 

  44. Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE. 2007;2(8):e809.

    PubMed  PubMed Central  Google Scholar 

  45. Kordi-Tamandani DM, Dahmardeh N, Torkamanzehi A. Evaluation of hypermethylation and expression pattern of GMR2, GMR5, GMR8, and GRIA3 in patients with schizophrenia. Gene. 2013;515(1):163–6.

    CAS  PubMed  Google Scholar 

  46. Carrard A, Salzmann A, Malafosse A, Karege F. Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder. J Affect Disord. 2011;132(3):450–3.

    CAS  PubMed  Google Scholar 

Download references

Funding

Medical Science and Technology Research Fund Project of Guangdong (No. A2021205); Social Welfare Science and Technology Research Project in Zhongshan (No. 2019B1107, No. 2018B1033, No. 2022B1061); Social Welfare Science and Technology Research Major Project in Zhongshan (No. 2018B1006, 2021B3019).

Author information

Authors and Affiliations

  1. Department of Psychiatry, The Third People’s Hospital, Zhongshan, 528451, Guangdong, People’s Republic of China

    Junjiao Ping, Jinming Yu, Zhiqiang Xing & Tingyun Jiang

  2. Joint Laboratory of Psychiatric Genetic Research, The Third People’s Hospital, Zhongshan, 528451, Guangdong, People’s Republic of China

    Junjiao Ping, Jiali Luo & Jie Zhang

  3. Department of Clinical Psychology, The Third People’s Hospital, Zhongshan, 528451, Guangdong, People’s Republic of China

    Baoguo Du

  4. Department of Early Intervention, The Third People’s Hospital, Zhongshan, 528451, Guangdong, People’s Republic of China

    Jing Wan & Caiying Huang

  5. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, 06510, USA

    Xingguang Luo

  6. Department of Psychiatry, Gannan Medical University, Ganzhou, 341000, Jiangxi , People’s Republic of China

    Jie Zhang

Authors
  1. Junjiao Ping
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Jing Wan
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Caiying Huang
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Jinming Yu
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Jiali Luo
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Zhiqiang Xing
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Xingguang Luo
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Baoguo Du
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Tingyun Jiang
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Jie Zhang
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

JZ and TYJ contributed to the conception and design of the study and provided approval for publication of the content. JJP designed the study and organized the database, performed statistical analysis, and were responsible for manuscript writing and editing. BGD and XGL conducted quality supervision and guidance for the project execution process. JL was responsible for the testing of experimental samples. JW, CYH, JMY and ZQX were responsible for clinical data collection and clinical evaluation. All authors reviewed and approved the final version of the manuscript.

Corresponding authors

Correspondence to Tingyun Jiang or Jie Zhang.

Ethics declarations

Ethics approval and consent to participate

Study protocol carried out in the research is followed in accordance with the ethical guidelines laid down as per the Declaration of Helsinki. The study was approved by the Ethics Committee of the Third People’s Hospital of Zhongshan, and written informed consent was obtained from either the patients or their guardians.

Competing interests

The authors declare that this research was conducted in the absence of any commercial or financial relationships that may be construed as a potential competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ping, J., Wan, J., Huang, C. et al. DNMT1 SNPs (rs2114724 and rs2228611) associated with positive symptoms in Chinese patients with schizophrenia. Ann Gen Psychiatry 22, 40 (2023). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12991-023-00466-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12991-023-00466-x

Keywords

Annals of General Psychiatry

ISSN: 1744-859X